Paper1985173
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Shpall EJ and 9 others. J Clin Oncol, 1991. Cited by 101 papers, by iCite.
Cite this record
ConductScience Library. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. Papers, record 1985173. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1985173
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
- PubMed
- Publication types
- Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Bone Marrow | Major topic |
| Bone Marrow Transplantation | Major topic |
| Breast Neoplasms | Major topic |
| Cyclophosphamide | Major topic |
| Adult | |
| Bone Neoplasms | |
| Brain Neoplasms | |
| Doxorubicin | |
| Drug Evaluation | |
| Female | |
| Fluorouracil | |
| Humans | |
| Methotrexate | |
| Middle Aged | |
| Neoplastic Stem Cells | |
| Survival Rate |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 22312362 | Oncolytic virotherapy for hematological malignancies. | Adv Virol | 2012 | https://conductscience.org/library/papers/22312362 | PubMed |
| 22146617 | High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later? | Biol Blood Marrow Transplant | 2012 | https://conductscience.org/library/papers/22146617 | PubMed |
| 20211576 | Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. | Cytokine Growth Factor Rev | 2010 | https://conductscience.org/library/papers/20211576 | PubMed |
| 16435011 | A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. | Bone Marrow Transplant | 2006 | https://conductscience.org/library/papers/16435011 | PubMed |
| 15368078 | Stem-cell transplantation for the treatment of advanced solid tumors. | Springer Semin Immunopathol | 2004 | https://conductscience.org/library/papers/15368078 | PubMed |
| 10464772 | The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation. | Mol Biotechnol | 1999 | https://conductscience.org/library/papers/10464772 | PubMed |
| 9764583 | High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9764583 | PubMed |
| 8958216 | Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. | J Clin Invest | 1996 | https://conductscience.org/library/papers/8958216 | PubMed |
| 8932871 | Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. | Breast Cancer Res Treat | 1996 | https://conductscience.org/library/papers/8932871 | PubMed |
| 8825758 | Dose-intensified treatment of breast cancer: current results. | J Mol Med (Berl) | 1995 | https://conductscience.org/library/papers/8825758 | PubMed |
| 8258193 | Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8258193 | PubMed |
| 8075009 | Current status of gene transfer into haemopoietic progenitor cells: application to Langerhans cell histiocytosis. | Br J Cancer Suppl | 1994 | https://conductscience.org/library/papers/8075009 | PubMed |
| 7691269 | New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. | Breast Cancer Res Treat | 1993 | https://conductscience.org/library/papers/7691269 | PubMed |
| 7531586 | The role and methodology for purging tumor from autologous bone marrow and peripheral blood progenitor cells. | Med Oncol | 1994 | https://conductscience.org/library/papers/7531586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1985173
GET https://conductscience.org/api/papers/v1/1985173/authors